Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each falling about 1.5%.
The iShares Biotechnology ETF (IBB) dropped 2.6%.
In corporate news, Guardant Health (GH) was up about 16% after the Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for its Shield blood test for colorectal cancer screening.
Quanterix (QTRX) shareholder Kent Lake said it opposed the firm's proposed deal with Akoya Biosciences (AKYA). Quanterix was up 2%, and Akoya gained 3.3%.
Arvinas (ARVN) and Pfizer (PFE) said a phase 3 trial of vepdegestrant to treat advanced or metastatic breast cancer met its primary endpoint in the estrogen receptor 1-mutant population, but didn't reach statistical significance in progression-free survival improvement in the intent-to-treat population. Arvinas tumbled 51%, and Pfizer was down 2.5%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。